<DOC>
	<DOCNO>NCT01134055</DOCNO>
	<brief_summary>The purpose study determine safety efficacy different dosage regimens pazopanib eye drop treatment neovascular age-related macular degeneration .</brief_summary>
	<brief_title>Dose Ranging Study Pazopanib Treat Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description>MD7110852 Phase 2b dose-ranging study design demonstrate 1 year efficacy safety pazopanib eye drop treatment neovascular age relate macular degeneration ( AMD ) subject whose disease currently manage anti-VEGF ( vascular endothelial growth factor ) injection therapy . Eye drop regimens double-masked placebo eye drop access open-label ranibizumab IVT injection need . The ranibizumab IVT injection every 4 week control arm open-label .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Men woman age ≥50 year . Active subfoveal choroidal neovascularization ( CNV ) lesion secondary AMD study eye : Total lesion area ≤12 disc area CNV ≥50 % total lesion area . AntiVEGF intravitreal injection experience need retreatment . Bestcorrected visual acuity least 24 letter ( equate approximately 20/320 Snellen equivalent well ) . Prior ocular investigational drug/device choroidal neovascularization , photodynamic therapy , radiation , subfoveal juxtafoveal focal laser photocoagulation . Prior failure antiVEGF intravitreal injection therapy . Recent ocular investigational drug/device nonCNV condition . Prior ocular surgery ( vitrectomy , scleral buckle , glaucoma filtering/shunt surgery ) . Cataract surgery permit ≥3 month posterior chamber intraocular lens . Centerfovea involvement follow : fibrosis , atrophy , serous retinal pigment epithelial detachment , retinal pigment epithelial tear . CNV either eye due cause . Clinical evidence diabetic retinopathy diabetic macular edema . Recent myocardial infarction cerebrovascular accident . Uncontrolled hypertension spite antihypertensive medication .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>wet AMD</keyword>
	<keyword>MD7110852</keyword>
	<keyword>age relate macular degeneration</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>pazopanib</keyword>
</DOC>